Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines
Metrics: PDF 389 views | HTML 875 views | ?
Helin Feng4,*, Heather Tillman2,*, Gang Wu3, Andrew M. Davidoff1 and Jun Yang1
1Department of Surgery, St Jude Children’s Research Hospital, Memphis, TN 38105, USA
2Department of Pathology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA
3Department of Computational Biology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA
4Department of Orthopedics, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, People’s Republic of China
*These authors contributed equally to this work
Jun Yang, email: Jun.Yang2@stjude.org
Keywords: polycomb repressive complex 2; EZH2; osteosarcoma; H3K27me3
Abbreviations: PRC2: polycomb repressive complex 2; OS: osteosarcoma; H3K27me3: trimethylation of lysine 27 on histone H3
Received: April 01, 2018 Accepted: May 08, 2018 Published: June 05, 2018
Osteosarcoma (OS) cell lines are widely used in understanding the biological functions of cancer, identification and validation of therapeutic targets, as well as in vitro or in vivo preclinical drug screening. Here we report there is a frequent loss-of-function of polycomb repressive complex 2 (PRC2) in OS cell lines but it is rare in tumor samples based on genomic sequencing data, western blotting and immunohistochemistry analysis of H3K27me3. U2OS and 143B cell lines have a complete loss of function of PRC2 and several others have partial loss. In OS tumor tissues, only 1 out of 14 has low expression of H3K27me3. Kaplan-Meier analysis indicates that high EZH2, the component of PRC2, is associated with poor metastasis-free survival. Our observations are to raise the alarm that particular caution should be taken when using OS cell line models to study the disease, functional genomics, therapeutic target validation, drug screening, and epigenetic studies. Nevertheless, these cell lines will become useful biological tools to dissect the functions of PRC2.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.